Telix and ITM merger creates radiopharmaceutical giant
Listed global biopharmaceutical company Telix Pharmaceuticals has announced a strategic merger with German radiopharmaceutical biotechnology company ITM Isotope Technologies Munich. The transaction signals a significant shift toward vertical integration in the radiopharmaceutical sector. The transaction, valued at US$1.65 billion upfront plus up to US$700 million in potential milestone payments, aims to secure Telix’s position as a global leader in precision…